Clovis' SNDA For Rubraca Gets Priority Review In The U.S.
Zacks Investment Research | Dec 06, 2017 03:09AM ET
Clovis Oncology (NASDAQ:CLVS) announced the FDA has granted priority review to its supplemental new drug application (sNDA) looking for label expansion of its marketed drug, Rubraca (rucaparib).
The sNDA is looking to expand Rubraca’s label as a maintenance treatment for patients with platinum-sensitive recurrent ovarian cancer regardless of a patient’s BRCA mutation status. With the FDA granting priority review, a response from the regulatory body is expected in Apr 6, 2018. Approval of the drug for this expanded indication will provide the company access to a wider population base of patients with ovarian cancer.
Notably, Rubraca is a PARP inhibitor, having received an accelerated approval in the United States in December 2016 for advanced ovarian cancer patients with deleterious BRCA mutation, previously treated with two or more chemotherapies.
Clovis’ shares are up almost 29.9% so far this year, significantly outperforming the industry ’s 0.9% rally during the period.
The sNDA was submitted in October, based on promising data from the confirmatory phase III study, ARIEL 3, announced in June. Rubraca demonstrated a meaningful impact in delaying disease recurrence in advanced ovarian cancer patients, who are either BRCA mutant or HRD positive.
We remind investors that Rubraca as a monotherapy is also under review in the EU for treating advanced ovarian cancer. An opinion is expected later this month.
Clovis is also planning to file a marketing authorization application in early 2018 for maintenance treatment in the EU following the potential approval as monotherapy.
A potential approval in the EU and the label expansion in the United States are expected to boost the drug’s potential. It has generated sales of nearly $38.5 million in the first nine months of 2017 post its launch in December last year.
However, Clovis’ Rubraca is facing competition from other PARP inhibitors including Tesaro, Inc.'s (NASDAQ:TSRO) Zejula and AstraZeneca's (NYSE:AZN) Lynparza as both these drugs are also approved to treat ovarian cancer irrespective of the BRCA-mutation.
Meanwhile, the second phase III confirmatory study, ARIEL4, is evaluating Rubraca compared with chemotherapy on patients, who have failed two prior lines of therapy. Clovis is also looking to expand Rubraca’s label into additional indications like prostrate, breast and pancreatic cancers among others either as monotherapy or in combination with other agents.
Get The News You Want
Other ongoing clinical analyses include phase II TRITON2 on prostate cancer and phase III TRITON3, a Tecentriq-Rubraca combination study on gynecologic cancers, sponsored by Roche (OTC:RHHBY) .
Zacks Rank
Cloviscarries a Zacks Rank #3 (Hold). You can see .
Wall Street’s Next Amazon (NASDAQ:AMZN)
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.